Novel osteoimmuno-oncology© therapies for cancer patients with bone metastases
Business concept
OncoBone Therapeutics was established in UK in March 2021 by four directors/co-founders with strong scientific and corporate experience in oncology drug development. The company develops novel therapies for cancer patients with bone metastases. Global cancer burden and cancer deaths are rapidly increasing, and metastases are the primary cause of cancer death. Bone is a major site of metastasis in several cancers, with breast and prostate cancer being most affected. Only about 5% of cancer patients with bone metastases are alive five years after the diagnosis. In the USA alone, over 350,000 cancer patients die each year from bone metastases. With no effective therapies available, bone metastases are currently incurable and a high unmet medical need, and such therapies would have a huge impact on the healthcare sector.
For developing novel therapies to bone metastases, OncoBone Therapeutics utilizes a novel osteoimmuno-oncology (OIO) concept established by its founders. OIO refers to interactions of cancer, bone and immune cells, three compartments important in regulating growth of bone metastases that should all be targeted when developing effective and safe therapies for bone metastases. OncoBone Therapeutics will confirm efficacy of its therapeutic assets utilizing its preclinical Bone Metastasis Technology Platform, followed by regulatory safety studies to complete the IND-ready packages. The therapeutic assets are then outlicensed to larger pharma or biotech companies for clinical development.
